Stockreport

A Look At Bicara Therapeutics (BCAX) Valuation After New FICERA Clinical Data And Accelerated Approval Plan [Yahoo! Finance]

Bicara Therapeutics Inc.  (BCAX) 
PDF Bicara Therapeutics (BCAX) is back on investors' radar after reporting clinical data for its FICERA program, which showed a 54% overall response rate and a 21% complete [Read more]